BiotechTube
Navire Pharma

Navire Pharma

San Francisco, United States· Est.
navirepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Navire Pharma is a private, pre-revenue biotech founded in 2015, specializing in SHP2 inhibitor therapeutics for oncology. Its core technology platform targets the SHP2 phosphatase, a key node in multiple oncogenic signaling pathways like RAS-MAPK, with the goal of addressing tumor resistance. The company's most advanced assets are in early clinical development, primarily focused on non-small cell lung cancer and other solid tumors. Navire's strategy involves leveraging its expertise to develop best-in-class inhibitors that could be used alongside existing targeted therapies or immunotherapies.

Oncology

Technology Platform

Structure-based drug design platform for allosteric small molecule inhibitors of SHP2 phosphatase.

Funding History

1
Total raised:$60M
Series A$60M

Opportunities

SHP2 inhibitors represent a promising backbone for combination regimens in oncology, with potential to overcome resistance to a wide array of targeted therapies and immunotherapies.
The large and growing market for targeted cancer therapies, especially in RAS-driven cancers, provides a substantial commercial opportunity for a successful agent.

Risk Factors

The novel mechanism of SHP2 inhibition carries inherent clinical development risk, and the competitive landscape is crowded with several well-funded rivals.
The company's pre-revenue status and dependence on future financing rounds introduce significant financial and dilution risk.

Competitive Landscape

Navire operates in a highly competitive space with multiple companies developing SHP2 inhibitors, including Revolution Medicines (RMC-4630), Novartis (TNO155), Relay Therapeutics (RLY-1971), and Erasca. Differentiation will depend on clinical efficacy, safety profile, and successful execution of combination strategies.

More companies in Small Molecule Drugs →More companies in United States →